Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3699079 | 0.99 | NTRK1 (0.44) | NTRK1BRAFP2RY1NAMPTTRPV1 | |
| SCHEMBL15054194 | 0.93 | NTRK1 (0.43) | NTRK1BRAFP2RY1NAMPTTRPV1 | |
| SCHEMBL3703952 | 0.93 | NTRK1 (0.53) | NTRK1P2RY1TRPV1STING1 | |
| Hydrochloric Acid SCHEMBL3705741 | 0.92 | NTRK1 (0.53) | NTRK1P2RY1TRPV1STING1 | |
| SCHEMBL3696934 | 0.90 | BRAF (0.44) | BRAFNAMPTFLT3KDRPTGER3 | |
| SCHEMBL3709404 | 0.89 | PTGER3 (0.49) | TRPV1PTGER3 | |
| SCHEMBL3699351 | 0.89 | NTRK1 (0.41) | NTRK1P2RY1NAMPTTRPV1CFD | |
| SCHEMBL3707797 | 0.89 | TRPV1 (0.49) | BRAFP2RY1TRPV1KDR | |
| Hydrochloric Acid SCHEMBL3697629 | 0.89 | NTRK1 (0.41) | NTRK1P2RY1NAMPTTRPV1CFD | |
| Hydrochloric Acid SCHEMBL3695606 | 0.89 | PTGER3 (0.49) | TRPV1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | claimed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | claimed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | NTRK1 817/4885BRAF 114/4885P2RY1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.